Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery
Article first published online: 21 MAR 2011
© 2011 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 33, Issue 10, pages 1152–1161, May 2011
How to Cite
Gubergrits, N., Malecka-Panas, E., Lehman, G. A., Vasileva, G., Shen, Y., Sander-Struckmeier, S., Caras, S. and Whitcomb, D. C. (2011), A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. Alimentary Pharmacology & Therapeutics, 33: 1152–1161. doi: 10.1111/j.1365-2036.2011.04631.x
- Issue published online: 13 APR 2011
- Article first published online: 21 MAR 2011
- Publication data Submitted 23 December 2010 First decision 29 December 2010 Resubmitted 28 February 2011 Accepted 1 March 2011 EV Pub Online 21 March 2011
Aliment Pharmacol Ther 2011; 33: 1152–1161
Background Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS).
Aim To assess the long-term safety and efficacy of pancrelipase (pancreatin) delayed-release capsules (Creon) in this population.
Methods This was a 6-month, open-label extension of a 7-day, double-blind, placebo-controlled study enrolling patients ≥18 years old with confirmed EPI due to CP or PS who were previously receiving PERT. Patients received individualised pancrelipase doses as directed by investigators (administered as Creon 24 000-lipase unit capsules).
Results Overall, 48 of 51 patients completed the open-label phase; one withdrew due to the unrelated treatment-emergent adverse event (TEAE) of cutaneous burns and two were lost to follow-up. The mean age was 50.9 years, 70.6% of patients were male, 76.5% had CP and 23.5% had undergone PS. The mean ± s.d. pancrelipase dose was 186 960 ± 74 640 lipase units/day. TEAEs were reported by 22 patients (43.1%) overall. Only four patients (7.8%) had TEAEs that were considered treatment related. From double-blind phase baseline to end of the open-label period, subjects achieved a mean ± s.d. body weight increase of 2.7 ± 3.4 kg (P < 0.0001) and change in daily stool frequency of −1.0 ± 1.3 (P < 0.001). Improvements in abdominal pain, flatulence and stool consistency were observed.
Conclusions Pancrelipase was well tolerated over 6 months and resulted in statistically significant weight gain and reduced stool frequency in patients with EPI due to CP or PS previously managed with standard PERT.